Korean J Obstet Gynecol.  1997 May;40(5):1037-1043.

The Effects of Conjugated Equine Estrogens Plus Dydrogesterone on Lipid and Bone Metabolism inPostmenopausal Women

• Chough SY
• Lee JK
• Hur JY
• Saw HS
• Park YK
• Ju KS
• Im IS
• Lee KN

Abstract

The addition of a monthly course of progesterone decrease the incidence of endometrialhyperplasia and endometrial carcinoma. The progesterones used in hormonal replacementtherapy(HRT) differ markedly in their progesteronic, androgenic and even estrogenicactivities. These characteristics may influence both symptomatic and metabolic side effects.The purpose of this study was to examine effect of bone and lipid metabolism inpostmenopausal women treated with conjugated equine estrogens plus dydrogesterone.A total 131 postmenopausal women(surgical menopause=95, natural menopause=36)and not-treated postmenopausal women(control=22) were invited to participate in thisstudy. Patients were divided into groups which had received conjugated equine estrogen(CEE)0.625 mg/day 21-day-cycle each month(n=20), CEE 0.625 mg/day plus Dydrogesterone 10mg/day 10-day-cycle each month(n=111), and no treatment control group(n=20).Serum lipid and lipoprotein(Triglyceride, Total cholesterol, High density lipoprotein, Lowdensity lipoprotein) and serum osteocalcin, urinary Deoxypyridinoline were examined in allpatients.There were no significant differences in bone and lipid metabolism between CEE andCEE plus Dydrogesterone groups.In conclusion, Dydrogesterone may be used safely in postmenopausal women withoutMetabolic side effect.

Keyword

Hormone replacement therapy; Lipid metabolism; Bone metabolism; Dydrogesterone

MeSH Terms

Cholesterol
Dydrogesterone*
Endometrial Neoplasms
Estrogens, Conjugated (USP)*
Female
Hormone Replacement Therapy
Humans
Incidence
Lipid Metabolism
Lipoproteins
Metabolism*
Osteocalcin
Progesterone
Cholesterol
Dydrogesterone
Estrogens, Conjugated (USP)
Lipoproteins
Osteocalcin
Progesterone